Canadian Consensus Guidelines for the Optimal Use of Maraviroc in the Treatment of HIV‐Infected Adults | Zendy

Anita Rachlis | Zendy; Marianne Harris | Zendy; Richard Lalonde | Zendy; Stephen D. Shafran | Zendy; Cécile Tremblay | Zendy; Mark A. Wainberg | Zendy; Sharon Walmsley | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Canadian Consensus Guidelines for the Optimal Use of Maraviroc in the Treatment of HIV‐Infected Adults

Author(s) -

Anita Rachlis,

Marianne Harris,

Richard Lalonde,

Stephen D. Shafran,

Cécile Tremblay,

Mark A. Wainberg,

Sharon Walmsley

Publication year - 2010

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 38

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2010/303474

Subject(s) - maraviroc , human immunodeficiency virus (hiv) , ccr5 receptor antagonist , virology , medicine , consensus conference , chemokine , receptor , chemokine receptor

A Canadian group, consisting of six physicians and an HIV researcher with significant experience and knowledge in HIV management, reviewed the available data and developed guidelines for Canadian health care providers (who treat HIV infection) on the appropriate use of maraviroc (UK-427,857) in HIV-infected adults.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research